Home Intangible Assets Alcon Inc. Announces Impairments of Property, Plant & Equipment and Intangible Assets for Three Months Ended March 31, 2026

Intangible Assets

Alcon Inc. Announces Impairments of Property, Plant & Equipment and Intangible Assets for Three Months Ended March 31, 2026

ByAmeliaMay 8, 20262 Mins read9

Market Closed – Swiss Exchange			5-day change	1st Jan Change
49.17 ^CHF	-2.29%		-15.54%	-22.30%

Published on 05/05/2026
at 04:30 pm EDT

S&P Capital IQ

Alcon Inc. announced Impairments of property, plant & equipment and intangible assets for three months ended March 31, 2026. For the quarter, the company reported the Impairments of property, plant & equipment and intangible assets of $38 million.

08:52am	A lot of noise, little impact?
05:39am	Bernstein Keeps Alcon at Outperform After Q1 Results; Estimates, Price Target Revised	MT
May. 07	Needham Trims Price Target on Alcon to $95 From $100, Keeps Buy Rating	MT
May. 06	Alcon Shares Fall After Q1 Revenue Miss	MT
May. 06	Alcon Q1 Shares Fall After Q1 Revenue Miss	MT
May. 06	Alcon: Results weren’t bad; today’s correction is a buying opportunity
May. 06	Swiss Market Index Rallies; Alcon, Logitech Shares Fall	MT
May. 06	Alcon Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Investors Can’t Get Enough of Chips
May. 06	Swiss eye care firm Alcon’s quarterly revenue rises less than expected	RE
May. 06	Alcon Price Target Declines as AlphaValue/Baader Cuts Estimates on Rising Competition, Expenses	MT
May. 06	Swiss stocks – Factors to watch on May 6	RE
May. 05	Alcon Logs Lower Q1 Net Income; Net Sales, Other Revenue Rise	MT
May. 05	Earnings Flash (ALC) Alcon Posts Q1 Revenue $2.69B, vs. FactSet Est of $2.7B	MT
May. 05	Alcon Q1 Core Earnings, Revenue Rise; 2026 EPS Outlook Revised	MT

Duration

Period

Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows:

– ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors;

– vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.).

At the end of 2025, the group operated 17 production sites worldwide.

Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).